Corneal neovascularization happens when new blood vessels grow into the clear front window of the eye. It can cause redness, light sensitivity, irritation, and blurry vision, and early symptoms of corneal neovascularization may feel like gritty discomfort. Many people with corneal neovascularization have it after long-term contact lens wear, eye surface inflammation, infection, or injury. It can affect any age and tends to persist or worsen if the trigger continues, but vision often stabilizes with treatment. Care usually includes treating the cause, using steroid or anti‑VEGF eye drops or injections, improving contact lens hygiene or fit, and sometimes laser or surgery, and it is rarely life-threatening but can threaten sight if untreated.
Overview
Corneal neovascularizationSymptoms
Corneal neovascularization can cause worsening eye redness, irritation, and light sensitivity, with blurry vision or halos. Some feel a gritty or aching eye. Doctors may see new blood vessels growing into the normally clear cornea.
Outlook and prognosis
Most people with corneal neovascularization do well when the cause is treated early and the new vessels are quieted. Vision often stabilizes, and symptoms like light sensitivity lessen. Delays or repeated flare-ups can raise the risk of scarring and vision loss.
Causes and risk factors
Common causes of corneal neovascularization include corneal hypoxia from tight or extended-wear contact lenses, infections, inflammation, dry eye, trauma, chemical burns, or surgery. Risk increases with poor lens hygiene, smoking, ocular surface disease, autoimmune disorders, and rare genetic corneal conditions.
Genetic influences
Genetics plays a smaller role in corneal neovascularization than environment and eye injury. Variations that affect corneal healing, inflammation, or lipid handling can raise risk. Family history of disorders like aniridia or lipid dystrophies may predispose some people.
Diagnosis
The diagnosis of corneal neovascularization starts with a slit‑lamp eye exam to spot new vessels. Doctors may use fluorescein dye, corneal photos, or OCT/fluorescein angiography to map them. Vision tests and contact lens or inflammation history help.
Treatment and drugs
Treatment for corneal neovascularization aims to quiet inflammation, stop new vessel growth, and protect vision. Options can include lubricating drops, steroid or anti-VEGF eye drops/injections, managing contact lens fit, treating infections, and, if needed, laser or surgery. Regular follow-up tracks healing and adjusts therapy.
Symptoms
Vision may look a little hazy, lights can feel harsh, and the eye may sting or feel gritty during the day. Corneal neovascularization happens when new blood vessels grow into the clear front of the eye, and the early symptoms of corneal neovascularization are often mild and easy to miss. As changes build, some people notice more glare, redness, and trouble with contact lenses. Symptoms vary from person to person and can change over time.
Many people notice nothing at first, especially if only a small area is affected. Early changes in corneal neovascularization can be silent until irritation or blur develops.
Vision can look soft or smeared, especially when reading or using screens. Blurring from corneal neovascularization may come and go at first.
Bright light, sunlight, or headlights may feel uncomfortable or painful. You might notice squinting more or reaching for sunglasses indoors on bad days.
The white of the eye can look pink or bloodshot. Redness may worsen after long days or extended screen or contact lens use.
How people usually first notice Corneal neovascularization?
People often first notice corneal neovascularization when one eye becomes red and irritated more often than usual, especially if they wear contact lenses for long hours, sleep in them, or have a poorly fitting lens. You might feel a gritty or burning sensation, light sensitivity, or see a drop in clarity or contrast, and an eye exam may reveal new, fine blood vessels creeping from the white of the eye toward the clear cornea. For many, the “first signs of corneal neovascularization” show up at a routine contact lens check, where the optometrist spots those tiny vessels before vision changes become obvious.
Types of Corneal neovascularization
Corneal neovascularization means new blood vessels growing into the normally clear cornea. Daily life impact can range from light sensitivity and blurry or hazy vision to irritation that feels like something is in the eye. Clinicians often describe them in these categories: superficial vessels, deeper stromal vessels, and mixed patterns, which helps predict symptoms and scarring risk. Not everyone will experience every type.
Superficial vessels
New, fine vessels creep in from the surface layer just beneath the clear coating. Vision may blur slightly and eyes can look red, with irritation or burning that worsens in bright light. These vessels often respond best to removing triggers like tight contact lenses and dryness.
Deep stromal vessels
Thicker vessels grow deeper in the corneal layers and can reach toward the visual center. People may notice more pronounced blur, glare, and ghosting of images, especially at night. This pattern carries a higher risk of scarring and lasting vision changes.
Mixed pattern
Both surface and deep vessels are present, and symptoms don’t always look the same for everyone. Some may have fluctuating blur with light sensitivity and a gritty feeling that comes and goes. Doctors may tailor treatment by targeting dryness, inflammation, and contact lens fit together.
Sectoral spread
Vessels grow in one quadrant or wedge of the cornea, often from a local trigger like a poorly fitting lens edge. Vision changes may be mild at first and more noticeable when that area crosses the line of sight. Early attention can limit further spread.
Pan-corneal spread
Vessels extend around much of the corneal edge and sometimes toward the center. People often report significant blur, glare, and halos, and may be more sensitive to wind or smoke. This is one of the more severe types of corneal neovascularization and may need layered treatment.
Active versus quiescent
Active vessels look bright red and leak fluid, while quiescent ones appear darker and more stable. Active phases tend to cause more irritation and light sensitivity. Knowing which phase you’re in can guide timing of therapy and follow-up when discussing types of corneal neovascularization.
What genetics can tell you about symptoms
Some people with variants in VEGF or HIF1A genes develop faster, more aggressive corneal blood vessel growth, which can blur vision, cause light sensitivity, and persistent eye redness. Changes in MMP genes may worsen scarring and swelling, increasing pain and visual haze.
Causes and risk factors
Wearing contact lenses too long, sleeping in them, or using low-oxygen lenses increases the risk of corneal neovascularization.
Chronic surface irritation from infections, severe dry eye, allergies, eyelid problems, chemical burns, or past eye surgery can trigger new vessel growth.
Smoke, dust, polluted air, and strong sunlight can worsen inflammation and raise risk, especially when the eye stays irritated.
Some rare inherited eye conditions can predispose people, and doctors distinguish between risk factors you can change and those you can’t.
Early symptoms of corneal neovascularization may appear after long periods of lens wear or irritation, but some people have no warning signs until an exam.
Environmental and biological risk factors
When tiny blood vessels start growing into the normally clear cornea, vision can blur and light may sting. This process, called corneal neovascularization, is often set in motion by oxygen shortage or long-standing surface inflammation. Doctors often group risks into internal (biological) and external (environmental). Below are key environmental and biological risk factors for corneal neovascularization.
Low-oxygen or poorly fitting lenses can starve the cornea of oxygen. This strain can trigger corneal neovascularization as the eye tries to bring in more blood. Lens solution preservatives can also irritate the surface.
Anything that limits oxygen reaching the cornea, like tight eye dressings or chronic swelling, promotes vessel growth. Prolonged low oxygen pushes the tissue toward invading blood vessels.
Ongoing irritation from allergies or eyelid inflammation sends growth signals that attract vessels. Over time, this can lead to corneal neovascularization. Seasonal peaks in allergens can intensify this effect.
Bacterial, viral, or parasitic infections inflame and weaken the surface. The healing response can sprout new vessels into the normally clear tissue. Severe or repeated infections make corneal neovascularization more likely.
Genetic risk factors
Genetic factors can set the stage for abnormal blood vessel growth into the cornea, often by disrupting the surface’s barrier or by tipping the balance between growth signals and natural brakes. Risk is not destiny—it varies widely between individuals. Several inherited syndromes and gene changes raise the chance of corneal neovascularization through limbal stem cell deficiency or chronic surface inflammation. These influences may be present long before early symptoms of corneal neovascularization are noticed.
PAX6 aniridia: Changes in the PAX6 gene that cause aniridia can lead to limbal stem cell deficiency. This weakens the corneal barrier and often triggers corneal neovascularization. Vessels may advance gradually if the surface stays unstable.
TP63 syndromes: Variants in TP63 (such as EEC syndrome) can damage the ocular surface and its stem cells. The resulting chronic keratitis encourages new vessel growth. This can culminate in corneal neovascularization affecting the visual axis.
GJB2 KID syndrome: KID syndrome from GJB2 changes leads to persistent eye surface inflammation and dryness. That environment favors corneal neovascularization. Flares can settle, but repeated episodes may leave lasting haze.
FOXC1/PITX2 changes: Anterior segment dysgenesis linked to FOXC1 or PITX2 can impair the limbal region. When that barrier fails, corneal neovascularization becomes more likely. Regular specialist follow-up helps track changes over time.
TGFBI dystrophies: Inherited TGFBI-related corneal dystrophies cause recurrent surface breakdown and scarring. Repeated injury can invite blood vessels into normally clear layers, leading to corneal neovascularization. Over years, this may dim contrast and clarity.
Telomere disorders: Conditions such as dyskeratosis congenita affect tissue renewal, including limbal stem cells. Poor healing increases vulnerability to vessel ingrowth on the cornea. Genetic counseling can guide testing and family planning.
HLA risk alleles: Certain HLA types are linked to autoimmune eye surface disease with scarring. This scarring often drives new corneal vessels. Family members may share HLA patterns, but expression and severity differ.
Sensory neuropathies: Hereditary sensory neuropathies reduce corneal sensation and the blink reflex. A numb, exposed surface heals poorly and can sprout abnormal vessels. Eye protection strategies become important in daily life.
Meesmann dystrophy: Changes in KRT3 or KRT12 make the corneal surface fragile with recurrent erosions. Chronic breakdown can lead to superficial vessel growth at the edges. Severity ranges from mild irritation to vision blur during flares.
Lifestyle risk factors
Lifestyle habits that increase corneal hypoxia, inflammation, or surface micro-injury can promote abnormal blood vessel growth in the cornea. This overview focuses on lifestyle risk factors for Corneal neovascularization and practical ways to reduce them. While medical causes require clinician care, everyday choices around contact lens use, eye hygiene, smoking, and diet can meaningfully influence how lifestyle affects Corneal neovascularization.
Extended hours of wear reduce corneal oxygen and can trigger neovascular growth. Limiting wear time and choosing high–oxygen-permeable lenses reduce the hypoxic drive.
Overnight wear creates prolonged hypoxia and microtrauma that stimulate vessel ingrowth. Remove lenses before sleep unless you are on a prescribed extended-wear schedule and closely monitored.
Deposits and biofilm increase inflammation, raising pro-angiogenic signals in the cornea. Rub-and-rinse cleaning after each wear and regular case replacement lower this inflammatory load.
Tobacco smoke and nicotine increase ocular surface inflammation and VEGF, promoting corneal neovascularization. Quitting reduces angiogenic signaling and improves corneal healing.
Risk prevention
Corneal neovascularization often develops when the clear cornea is stressed by low oxygen, ongoing irritation, or infection. Reducing these triggers can lower the chance it starts or gets worse. Prevention works best when combined with regular check-ups. If you wear contact lenses or have dry, allergic, or inflamed eyes, targeted steps can make a real difference.
Avoid sleeping in lenses unless specifically prescribed. Give your eyes daily breaks from contacts to reduce low-oxygen stress.
Choose lenses with high oxygen permeability if you wear them many hours. This can reduce the risk of corneal neovascularization linked to hypoxia.
Ensure your lenses fit well and move smoothly with each blink. Poor fit can rub the cornea and raise the risk of new vessel growth.
Wash and dry hands before handling lenses, and use fresh solution each time. Rubbing and rinsing lenses as directed lowers infection and inflammation risks.
Transmission
Corneal neovascularization isn’t contagious—you can’t catch it from someone else or spread it through casual contact. It also isn’t an inherited disorder on its own; corneal neovascularization usually develops as a response to low oxygen to the cornea (for example from long or overnight contact lens wear), chronic irritation or inflammation, prior eye surgery, or a corneal infection.
If an infection triggers it, only the infection itself may be contagious, not the new blood vessel growth. In short, there is no person-to-person transmission of corneal neovascularization.
When to test your genes
Consider genetic testing if corneal neovascularization is severe, unexplained, recurs despite treatment, or appears alongside other eye issues, especially with a family history of corneal disorders. Testing can uncover inherited dystrophies or systemic conditions that change monitoring, medication choices, or transplant planning. Discuss timing with an ophthalmologist and a genetics professional.
Diagnosis
You might notice ongoing redness, irritation, or light sensitivity that makes reading or driving at night harder. Some also feel a gritty sensation or see blur that doesn’t improve with blinking. Understanding how corneal neovascularization is diagnosed can help you know what to expect during the eye exam. Doctors usually begin with a careful conversation about symptoms and risk factors, then use simple office tests to look closely at the cornea.
Your eye doctor asks about redness, discomfort, light sensitivity, and blurred vision. They’ll review recent infections, injuries, and dry eye symptoms to spot likely triggers. Contact lens habits are a key part of this discussion.
The team checks how long you wear lenses, overnight use, and lens type. Poor oxygen flow to the cornea can drive new vessel growth. Fit and hygiene are reviewed to find modifiable risks.
A standard chart test measures how clearly you see at distance and near. This helps track vision changes over time. It also guides whether treatment is urgent.
A microscope with bright light shows new blood vessels on or within the cornea. The doctor notes the depth, pattern, and any active inflammation or scarring. Findings help stage severity and guide treatment.
Stages of Corneal neovascularization
Corneal neovascularization does not have defined progression stages. It tends to vary based on the cause and how long the eye has been irritated or oxygen-deprived, so doctors describe it by where the new vessels grow (surface or deeper layers), how far they extend, and whether they’re active or quiet rather than by fixed stages. Different tests may be suggested to help map the vessels and check for inflammation, such as a slit-lamp exam, dye drops to highlight vessels, and photos or scans to compare over time. If you notice early symptoms of corneal neovascularization like new redness, irritation, light sensitivity, or blurry vision, an eye exam can confirm what’s happening and monitor it over time.
Outlook and prognosis
Vision changes from corneal neovascularization can range from mild blur and light sensitivity to more noticeable haze that makes night driving or reading small print hard. Everyone’s journey looks a little different. Some people have only a few tiny new vessels that quiet down with treatment, while others develop more extensive growth that threatens the clear center of the cornea and raises the risk of scarring.
Looking at the long-term picture can be helpful. Prognosis refers to how a condition tends to change or stabilize over time. With timely care—treating the trigger like contact lens overuse, dry eye, infection, or inflammation—many people stabilize and keep good day-to-day function. When vessel growth is aggressive or reaches the visual axis, the outlook can include permanent blur, higher chances of recurrent ulcers, and in some cases the need for procedures such as anti-VEGF injections, laser, or corneal transplant to protect vision. Severe corneal neovascularization is not usually life-threatening, but it can be sight-threatening; the main “mortality” concern here is loss of vision rather than risk to overall life span.
Over time, most people do better when early symptoms of corneal neovascularization—worsening redness, ache, light sensitivity, or new blur—prompt a quick eye exam and targeted treatment. With ongoing care, many people maintain stable vision, especially if they switch to safer contact lens habits, treat dryness or allergies, and keep inflammation under control. The risk of needing a future transplant is higher when new vessels are deep, numerous, or long-standing, but even then, careful follow-up and therapy can improve graft survival and reduce flare-ups. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Corneal neovascularization can change the cornea over time, which may affect clarity and comfort. Long-term effects vary widely, depending on how many new vessels grow, how deep they go, and what caused them. Many people don’t notice early symptoms of corneal neovascularization because the changes can start at the edge of the cornea and creep inward. Over months to years, these changes can lead to scarring, flare-ups, and, for some, reduced vision that can come and go or slowly worsen.
New vessels and swelling can scatter light and blur vision. Over time this can lower contrast and sharpness, especially in low light.
Repeated inflammation and vessel growth can leave permanent haze or scars. Scarring can reduce best-corrected vision even with glasses or contacts.
Many feel glare, halos, or aching in bright light. This can make night driving or screen time uncomfortable during flare-ups.
Periodic redness and irritation may return as vessels stay active. These episodes can further damage the cornea if they continue.
How is it to live with Corneal neovascularization?
Living with corneal neovascularization can feel like looking through a window that fogs unpredictably—some days sharp, other days hazy, with light glare or eye fatigue making screens, night driving, or long reading sessions harder. Many notice irritation, redness, and sensitivity to bright light, and flare-ups can demand frequent drops, careful contact lens limits, and regular eye appointments. This rhythm affects people around you too; partners or coworkers may see you dimming lights, taking breaks, or avoiding dry, dusty places, and their understanding helps you protect your vision. With consistent care and trigger awareness, many keep daily routines steady while preventing setbacks.
Treatment and drugs
Corneal neovascularization treatment focuses on calming inflammation, protecting the cornea, and stopping new blood vessels from growing to preserve vision. Doctors often start with treating the trigger—such as dry eye, contact lens overuse, infection, or eyelid inflammation—then add anti‑inflammatory eye drops (like corticosteroids) and lubricating drops; a doctor may adjust your dose to balance benefits and side effects. To directly target abnormal vessels, options include anti‑VEGF injections around the eye, laser therapy, or fine‑needle cautery, with repeat treatments sometimes needed if vessels return. If contact lenses are involved, switching to highly oxygen‑permeable lenses, improving lens hygiene, or taking a break can help; severe scarring or thinning may require procedures like amniotic membrane grafts or, rarely, corneal transplant. Supportive care can make a real difference in how you feel day to day, so ask your doctor about the best starting point for you.
Non-drug treatment
For many, day-to-day steps—especially around contact lens wear—make the biggest difference in easing eye redness and protecting vision. Spotting early symptoms of corneal neovascularization, like new redness near the colored part of the eye or lens discomfort, helps your eye doctor act sooner. Alongside medicines, non-drug therapies can reduce triggers, calm irritation, and target the tiny feeder vessels that keep growing. Your eye team will match options to the cause, how active the vessels are, and your visual needs.
Taking a break from lenses gives the cornea time to recover. Switching to high-oxygen (silicone hydrogel) or daily disposable lenses and avoiding overnight wear can lower the drive for new vessels. A careful refit can also improve oxygen flow.
Rubbing and rinsing lenses, replacing cases, and never topping off solution reduce irritation that can fuel vessel growth. Cutting wear time and skipping sleep in lenses also protects the cornea. These habits support recovery from corneal neovascularization.
Sunglasses with UV protection lower surface inflammation from sunlight. This can ease irritation that keeps vessels active. A brimmed hat adds another layer of defense.
Gentle lid scrubs and warm compresses help calm eyelid inflammation. Cleaner lids mean fewer inflammatory signals reaching the cornea. This can slow worsening of corneal neovascularization.
Your genes may have an impact on how drugs work for you
Sometimes two people take the same eye drops for corneal neovascularization and only one sees steady improvement—genetic differences can help explain that. Variations in genes that affect drug processing or VEGF pathways can influence how well anti‑inflammatory or anti‑VEGF treatments work.
Pharmacological treatments
Medicines for corneal neovascularization aim to calm surface inflammation and stop new, fragile blood vessels from growing into the clear cornea. Doctors often combine treatments and adjust them over time based on how your eye responds. Not everyone responds to the same medication in the same way. Even if early symptoms of corneal neovascularization are mild, treatment may be started to protect clarity and vision long term.
Prednisolone acetate 1%, dexamethasone, or loteprednol can quiet inflammation that fuels vessel growth. They may help shrink or stabilize abnormal vessels in corneal neovascularization. Your eye pressure will be monitored because steroids can raise it in some people.
Bevacizumab, ranibizumab, or aflibercept are given in or around the eye to block the growth signal (VEGF) that drives new vessels. This can help existing vessels regress and limit further spread. Infections are rare but serious, and your doctor will review risks and benefits.
Compounded bevacizumab eye drops are sometimes used off‑label to target surface vessels directly. Results vary, and drops may be tried when injections aren’t preferred or as an add‑on. Your clinician will outline how long to try them before judging benefit.
Cyclosporine 0.05–0.1% can reduce chronic corneal surface inflammation and lower the need for steroids. It may take several weeks to feel the full effect. A brief stinging sensation is common when starting.
Genetic influences
Most cases of corneal neovascularization develop after irritation, infection, autoimmune eye disease, or low oxygen from contact lens wear, but heredity can still play a role. Genetics is only one piece of the puzzle, but it can shape how likely new vessels are to grow into the cornea and how quickly they return after treatment. Differences in genes that regulate new blood-vessel growth and inflammation may make some people more prone to this problem or affect how severe it becomes. Rare inherited eye conditions that weaken the cornea’s surface or the limbal stem cells (the cells at the edge of the cornea that renew its surface) can also set the stage for corneal neovascularization and may cluster in families. These genetic influences do not change what early symptoms of corneal neovascularization feel like—such as redness, light sensitivity, or blurred vision—but they can affect who is most at risk and how you respond to medicines that block vessel growth or calm inflammation. If several relatives have significant corneal problems at a young age or recurring vessel growth, tell your eye doctor; they may consider referral for genetic counseling to discuss testing and family risk.
Is Corneal neovascularization genetic?
Genetics plays a smaller role in corneal neovascularization than environment and eye injury. Variations that affect corneal healing, inflammation, or lipid handling can raise risk. Family history of disorders like aniridia or lipid dystrophies may predispose some people.
Pharmacogenetics—how genetics influence drug effects
Treating corneal neovascularization often involves steroid eye drops, anti-VEGF medicines, and at times immune‑modulating drugs when inflammation is a driver. Genes can influence how quickly you process medicine, which can change the dose you need and your risk of side effects with drugs like tacrolimus or azathioprine used in more severe or systemic cases. With steroid drops, some people are “steroid responders” who develop a rise in eye pressure; this tendency has a genetic component, so regular pressure checks are important during treatment. Response to anti‑VEGF therapy can also vary from person to person, and inherited differences in the VEGF pathway may help explain why some eyes respond briskly while others need repeated treatments, but testing for this isn’t part of routine care. Pharmacogenetic testing isn’t routine for corneal neovascularization today, yet it can be useful when systemic immune‑modulating medicines are considered, helping guide safer dosing and monitoring. Genes are just one piece of the puzzle; contact lens wear, infections, scarring, other eye conditions, and overall health also shape how treatments work and which side effects show up.
Interactions with other conditions
Chronic eye surface problems—like allergic eye disease, long-standing eyelid inflammation, or past infections such as herpes simplex—can trigger or worsen corneal neovascularization by keeping the surface irritated and oxygen-starved. Another important aspect is how it may link with other diseases. Autoimmune conditions, including rheumatoid arthritis or Sjögren’s, often heighten inflammation, which can speed vessel growth into the normally clear cornea. In people who may need a corneal transplant, prior corneal neovascularization from infections or a cone-shaped cornea (keratoconus) can raise the risk of graft rejection because the new vessels let immune cells reach the transplant more easily. Skin and eyelid disorders like ocular rosacea can also aggravate the surface and feed into this process; sometimes early symptoms of corneal neovascularization are subtle and show up when the other condition is flaring. Let your eye care team know about all your diagnoses and treatments so they can plan care that calms the surface, protects vision, and addresses both the corneal neovascularization and any related disease.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of eyes becoming red, sensitive to light, and slowly losing clear vision after injuries or long illnesses. Healers tried soothing washes or protective coverings, and some learned that letting the eye “breathe” helped, while tight bandages or irritating salves made things worse. Over time, people saw that when the clear front window of the eye stayed inflamed or deprived of oxygen, small red lines crept in from the edge—new blood vessels where none should be.
First described in the medical literature as abnormal vessels invading the cornea, early reports came from infections, trauma, and poorly fitting glass or early plastic contact lenses. In the mid-20th century, as contact lenses became common, doctors linked extended wear and low-oxygen materials to corneal neovascularization, especially in those who slept in their lenses. With microscopes and slit-lamp exams, clinicians could map how far these vessels grew and how they sometimes leaked or scarred, clouding vision.
From early theories to modern research, the story of corneal neovascularization has followed advances in understanding inflammation and oxygen supply. Once antibiotics reduced severe eye infections, fewer cases came from ulcers, but autoimmune eye diseases, chemical injuries, herpes infections, and chronic eyelid inflammation remained important triggers. Laser tools and corneal photography allowed careful tracking, showing that even short spurts of low oxygen—like a long flight or a nap in thick lenses—could spur growth in vulnerable eyes.
In recent decades, awareness has grown that molecules acting like growth signals in the eye, especially those turned on by low oxygen and ongoing irritation, drive these vessels like a stuck accelerator. This shifted care from only removing triggers to also calming the growth signals. Eye drops that reduce inflammation, improved lens materials that deliver more oxygen, and better hygiene practices led to fewer new cases in contact lens users.
Building on this early work, scientists adapted treatments first used for blood vessel growth in other eye diseases. Carefully placed anti‑growth injections around the cornea, fine-spot lasers to close feeder vessels, and medications that quiet surface inflammation have helped many people. Surgeons refined corneal transplants and developed partial grafts, knowing that a quiet, vessel‑free cornea heals more clearly. Today, the history of corneal neovascularization guides practical steps: avoid chronic irritation, ensure adequate oxygen to the cornea, treat infections quickly, and use targeted therapies when vessels start to advance. Understanding how early symptoms of corneal neovascularization were recognized—redness that doesn’t fade, light sensitivity, and a creeping haze—has shaped modern eye care and improved the odds of keeping vision clear.